Physician profile
Vikramjeet Kumar
NPI 1841271269
$105,817.02
in general payments reported to CMS, 2019-2025
55 companies · $2,785 in 2025
The $2,785 reported for 2025 was more than what 82% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $26K · 2021: $20K · 2022: $17K · 2023: $8,910 · 2024: $6,273 · 2025: $2,785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Food and Beverage: $7,635 · Education: $174 · Travel and Lodging: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,000.00 |
| Food and Beverage | $7,634.94 |
| Education | $173.81 |
| Travel and Lodging | $159.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $36,546.65 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $32,659.41 | 2019-2025 | Wainua |
| Mannkind Corporation | $17,058.23 | 2019-2025 | Afrezza |
| Corcept Therapeutics | $4,597.73 | 2019-2025 | Korlym |
| Senseonics, Incorporated | $3,440.00 | 2020 | |
| Xeris Pharmaceuticals, INC. | $1,353.28 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Sanofi-Aventis U.S. LLC | $1,113.52 | 2019-2025 | |
| Lilly USA, LLC | $1,029.67 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Insulet Corporation | $951.67 | 2019-2024 | Omnipod |
| Dexcom, INC. | $791.26 | 2019-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $634.72 | 2019-2025 | Keytruda, Steglatro, Keytruda Qlex |
| Amgen INC. | $597.51 | 2024-2025 | Tepezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $447.01 | 2019-2023 | Ofev |
| Ascendis Pharma Endocrinology INC | $385.69 | 2024-2025 | Yorvipath |
| Bayer Healthcare Pharmaceuticals INC. | $339.18 | 2021-2025 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikramjeet Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.